JP2017502089A5 - - Google Patents

Download PDF

Info

Publication number
JP2017502089A5
JP2017502089A5 JP2016563885A JP2016563885A JP2017502089A5 JP 2017502089 A5 JP2017502089 A5 JP 2017502089A5 JP 2016563885 A JP2016563885 A JP 2016563885A JP 2016563885 A JP2016563885 A JP 2016563885A JP 2017502089 A5 JP2017502089 A5 JP 2017502089A5
Authority
JP
Japan
Prior art keywords
composition
pharmaceutically acceptable
acceptable salt
prostaglandin
preferably der
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016563885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502089A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/010771 external-priority patent/WO2015106068A1/en
Publication of JP2017502089A publication Critical patent/JP2017502089A/ja
Publication of JP2017502089A5 publication Critical patent/JP2017502089A5/ja
Pending legal-status Critical Current

Links

JP2016563885A 2014-01-10 2015-01-09 偏頭痛の処置 Pending JP2017502089A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925676P 2014-01-10 2014-01-10
US61/925,676 2014-01-10
PCT/US2015/010771 WO2015106068A1 (en) 2014-01-10 2015-01-09 Treatment of migraines

Publications (2)

Publication Number Publication Date
JP2017502089A JP2017502089A (ja) 2017-01-19
JP2017502089A5 true JP2017502089A5 (cg-RX-API-DMAC7.html) 2018-02-22

Family

ID=53524356

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016563885A Pending JP2017502089A (ja) 2014-01-10 2015-01-09 偏頭痛の処置

Country Status (5)

Country Link
US (2) US9913849B2 (cg-RX-API-DMAC7.html)
EP (1) EP3091985B1 (cg-RX-API-DMAC7.html)
JP (1) JP2017502089A (cg-RX-API-DMAC7.html)
CA (1) CA2935957C (cg-RX-API-DMAC7.html)
WO (1) WO2015106068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935957C (en) * 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs
CN113040835A (zh) * 2019-12-27 2021-06-29 四川大学华西医院 治疗卵圆孔未闭的装置在制备治疗癫痫和/或偏头痛的装置中的用途
WO2022081297A1 (en) * 2020-10-12 2022-04-21 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for lowering intracranial pressure by intranasal agent administration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4767619A (en) 1981-09-14 1988-08-30 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of National Defence Of Her Majesty's Canadian Government Burn wound dressing material
US4511563A (en) 1983-07-15 1985-04-16 Basf Wyandotte Corporation Clear analgesic gels with reduced tackiness
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3720147A1 (de) 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US4883660A (en) 1988-10-17 1989-11-28 Thames Pharmacal Co., Inc. Gel bases for pharmaceutical compositions
US5318780A (en) 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
DE4212105A1 (de) 1992-04-10 1993-10-14 Roehm Pharma Gmbh Nagellack zur Behandlung von Onychomykosen
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6224887B1 (en) 1998-02-09 2001-05-01 Macrochem Corporation Antifungal nail lacquer and method using same
US6231875B1 (en) 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
IL134241A (en) 2000-01-27 2006-06-11 Finetech Pharmaceutical Ltd Process for the preparation of latanoprost
IL143477A (en) 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
JP2003531824A (ja) 2000-02-01 2003-10-28 ケイマン ケミカル カムパニー,インク. フルプロステノールおよび関連プロスタグランジンF2α類似体の内部1,15−ラクトン、ならびに緑内障および眼高血圧の治療におけるそれらの使用
US6495124B1 (en) 2000-02-14 2002-12-17 Macrochem Corporation Antifungal nail lacquer and method using same
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
KR100581647B1 (ko) 2001-07-17 2006-05-22 파마시아 앤드 업존 캄파니 엘엘씨 라타노프로스트 제조를 위한 방법 및 중간체
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
EP1501530B1 (en) 2002-03-21 2009-02-18 Cayman Chemical Company Prostaglandin f2 alpha analogs in combination with antimicrobial for treating glaucoma
US20030049307A1 (en) 2002-08-15 2003-03-13 Gyurik Robert J. Pharmaceutical composition
US7109371B2 (en) 2004-01-05 2006-09-19 Johnson Matthey Public Limited Company Prostaglandin synthesis
PL1704141T3 (pl) 2004-01-05 2016-08-31 Nicox Sa Nitrooksypochodne prostaglandyn
EP1627610A1 (en) * 2004-08-21 2006-02-22 TLT Medical Ltd Drug delivery throug application in nails
ES2418153T3 (es) * 2006-03-08 2013-08-12 Cortria Corporation Terapia de combinación con inhibidores no selectivos de COX para prevenir lesiones gástricas relacionadas con COX
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
IL177762A0 (en) 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
FR2920309B1 (fr) 2007-08-28 2010-05-28 Galderma Res & Dev Utilisation de travoprost pour traiter la chute des cheveux
WO2009103150A1 (en) 2008-02-20 2009-08-27 Kevin David Smith Method for treating migraine headaches
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20080275118A1 (en) * 2008-06-12 2008-11-06 Shaw Mari M Health and cosmetic composition and regime for stimulating hair growth and thickening on the head, including the scalp, eyelashes, and eyebrows, and which discourages hair loss
EP2143712A1 (en) 2008-07-10 2010-01-13 Sandoz AG Improved Process for the Production of Prostaglandins and Prostaglandin Analogs
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
WO2010080915A1 (en) 2009-01-08 2010-07-15 Allergan, Inc. Compositions for enhancing nail growth
IT1393112B1 (it) 2009-02-27 2012-04-11 Sifavitor S R L Procedimento per la preparazione di derivati di prostaglandine
KR20120081227A (ko) 2009-11-02 2012-07-18 샹하이 테크웰 바이오파마슈티컬 컴퍼니, 리미티드 비마토프로스트 결정 및 그의 제조방법과 용도
ES2836808T3 (es) * 2011-04-05 2021-06-28 Optosolve Res & Development Ltd Tratamientos oftálmicos
CN103957875A (zh) 2011-10-05 2014-07-30 阿勒根公司 用于增强指甲健康的组合物
CA2935957C (en) * 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2021002322A (es) Nuevos metodos.
CN111601610A8 (zh) 使用布劳特氏菌属菌株治疗疾病的组合物和方法
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
JP2018531233A5 (cg-RX-API-DMAC7.html)
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
PE20241305A1 (es) Analogos de amilina
JP2014198723A5 (cg-RX-API-DMAC7.html)
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
JP2017222722A5 (cg-RX-API-DMAC7.html)
SV2016005145A (es) Polipéptidos cíclicos para el tratamiento de la insuficiencia cardiaca
MY207469A (en) Therapeutic compounds
JP2016512246A5 (cg-RX-API-DMAC7.html)
JP2017502089A5 (cg-RX-API-DMAC7.html)
CL2020001791A1 (es) Composiciones farmacéuticas para la piel tópicas que contienen cerdulatinib y usos de estas.
RU2016112257A (ru) Композиция для лечения гипертензии и/или фиброза
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
JP2017513944A5 (cg-RX-API-DMAC7.html)
JP2016538288A5 (cg-RX-API-DMAC7.html)
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
JP2016523943A5 (cg-RX-API-DMAC7.html)
TN2019000220A1 (en) Intranasal composition comprising betahistine
MX2021014093A (es) Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson.
WO2015183985A3 (en) Therapeutic compositions including naphthoquinones and uses thereof